Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015...
View ArticleEnanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in...
(Source: Enanta Pharmaceuticals Inc) Sustained virologic response 12 weeks post-treatment (SVR12) of 91 percent was achieved in Japanese patients with genotype 1b (GT1b) hepatitis C virus (HCV)...
View ArticleAbbVie Presents New Data for its Investigational Hepatitis C Treatment in...
(Source: AbbVie Inc) - Primary endpoint of 95 percent and secondary endpoint of 91 percent SVR12 achieved in genotype 1b hepatitis C virus infected Japanese patients without and with compensated...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
NORTH CHICAGO, Ill., Sept. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
(Source: AbbVie Inc) Data from 25 accepted abstracts include results from: -- AbbVie's investigational treatment in liver transplant recipients with recurrent genotype 1 (GT1) chronic hepatitis C virus...
View ArticleEnanta Announces JAMA Publication of Results from AbbVie’s Study of VIEKIRA...
(Source: Enanta Pharmaceuticals Inc) Enanta Announces JAMA Publication of Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Sept. 28, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and...
View ArticleAbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir...
(Source: AbbVie Inc) Mar 30, 2016 NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
View ArticleAbbVie Announces Real-World Data with VIEKIRAX®...
BARCELONA, Spain, April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505...
View ArticleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s...
(Source: Enanta Pharmaceuticals Inc) AbbVie reports 98 percent of previously untreatedgenotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVRin Phase 3b...
View ArticleEnanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Preliminary Data from AbbVie's Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ --...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
(Source: AbbVie Inc) - 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill. , June 24,...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
NORTH CHICAGO, Ill., April 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH CHICAGO,...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
(Source: AbbVie Inc) - 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline...
View ArticleEnanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless...
(Source: Enanta Pharmaceuticals Inc) 100 percent of genotype 1b (GT1b) patients who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVRin a post-hoc analysis,regardless of whether...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating...
View Article